Bio-Techne (NASDAQ:TECH) receives buy recommendation from Benchmark

Benchmark reiterated its buy recommendation for shares of Bio-Techne (NASDAQ:TECH – Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a price target of $95.00 on the biotechnology company’s stock. Several other brokerage firms…